pharmacy

Top considerations when determining whether to approve expensive drugsWeighing the ethics of approving expensive cancer drugs for patients facing terminal disease is a multifaceted endeavor. Here are some recommendations.
Payers strategize to manage opioid useHow managed care organizations manage opioid utilization and some of the limitations to those management strategies was a hot topic at the AMCP Annual Meeting.
Creating a ‘robust’ specialty pharmacy networkThe correct approach to take when creating a specialty pharmacy network is a key issue for healthcare executives.
FDA approvals for specialty drugs to pick up in 2017Numerous specialty medications, generics, and biosimilars, are expected to be approved this year for cancer, inflammatory and autoimmune diseases, and other indications.
Health policy changes could affect reimbursement: What to knowHere’s what a Vizient’s hospital leader survey says about the future of the Affordable Care Act (ACA) and other healthcare policies under the new Administration.
Poll: Few consumers trust health orgs, pharmaA new report has troubling findings for payers, providers, and technology companies. Here are the key takeaways, and reactions from experts.
Top 3 pharmacy challenges in 2017: Two-pronged solutionHere are three pharmacy challenges facing healthcare executives and a two-pronged solution to help solve them.
Top pharmacy challenges of 2017
Top pharmacy challenges of 2017High drug prices continue to plague payers, but various contributing factors intensify the problem.
Make it personal: Three ways to connect with healthcare consumers: Remembering to engage in healthy behavior can often slip to the bottom of our list of priorities. In a world where we need to be reminded and motivated to be the healthiest version of ourselves, the right nudges at the right time can help us get there.
How the presidential candidates plan to rein in pharma costs
How the presidential candidates plan to rein in pharma costsFind out where each presidential candidate stands on key issues related to pharmaceutical costs.